Thera-SAbDab

LEBRIKIZUMAB

>   Structural Summary
TherapeuticLebrikizumab
TargetIL13
Heavy ChainQVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS
Light ChainDIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK
100% seqID Fv Structure4i77 [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedChugai Pharmaceutical, Comprehensive Clinical Research Network, Dermira, Genentech, Roche, Tanox
Conditions Approvedna
Conditions ActiveAtopic dermatitis
Conditions DiscontinuedAsthma, Chronic obstructive pulmonary disease, Hodgkin's disease, Idiopathic pulmonary fibrosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]